Comparison of visual and anatomic outcomes of ranibizumab, aflibercept and dexamethasone implant after switch from bevacizumab in retinal vein occlusions

Poster Details

First Author: J.Hanhart ISRAEL

Co Author(s):    D. Zadok                             

Abstract Details


To determine and compare the visual and anatomic outcomes of eyes with macular edema secondary to retinal vein occlusion after switching therapy from bevacizumab to ranibizumab, aflibercept or dexamethasone implant.


Single retinal unit, Ophthalmology Department, Shaare Zedek Medical centre, Jerusalem.


37 eyes (37 patients) were included in this retrospective study: 15 eyes were switched to ranibizumab, 12 to aflibercept and 10 to dexamethasone. At 3,6 9 and 12 months, the outcome measures were visual acuity (VA) and central macular thickness (CMT) compared with baseline and pre-switch values.


The three groups were balanced at baseline and at switch. CMT had decreased from 430.11 ± 91.21 μm to 291.86 ± 43.87 μm (P < .001) one year after the switch. VA increased in 59.5% of the eyes, overall from 0.36 ± 0.20 to 0.50 ± 0.26 (P < .001). There was no differences between the groups in the CMT and VA outcomes at one year. We found a significant difference in the number of injections: 3.30 ±0.95 for dexamethasone, 6.50 ±2.11 for aflibercept and 8.27 ±2.37 for ranibizumab (P < .001).


Most of the eyes that failed initial bevacizumab therapy benefit from switching to another modality. The number of required injections during the first year after the switch varies: 3.3 with dexamethasone, 6.5 with aflibercept and 8.3 with ranibizumab.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy